Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Flumazenil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 known ✓ | P18507 | 16/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 16/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 16/20 | 1.00 |
| ▸ | GABRA1 known ✓ | P14867 | 15/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 14/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 14/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 10/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 8/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 4/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumazenil SCHEMBL29746432 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL5781309 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL11885881 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL79030 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL30305657 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL16187025 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL12484498 | 0.99 | GABRG2 (0.98) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29085132 | 0.97 | GABRG2 (0.94) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29025825 | 0.94 | GABRG2 (0.88) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL16479000 | 0.92 | GABRG2 (0.85) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217596-A1 | SUBSTITUTED 2,3-DIHYDRO-4H-BENZO[E][ 1,3] OXAZIN-4-ONE COMPOUNDS AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-10-16 | — | — | WO | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12590094-B2 | Compounds for the treatment of neurodegenerative and metabolic disorders | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260077139-A1 | SPACER DEVICE WITH FLOW RATE SPIROMETER | AEROVU TECHNOLOGIES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| EP-4192823-B9 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | SANIONA AS (DK) | 2026-03-18 | — | — | EP | disclosed |
| US-12569480-B2 | Methods of treating fibrosis using compounds that promote glucose oxidation | IMBRIA PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260060978-A1 | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS | IMBRIA PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12514993-B2 | Spacer device with flow rate spirometer | AEROVU TECHNOLOGIES, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| CN-107344938-B | Pyrazole-triazine derivative, preparation method thereof, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3992188-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3194033-B1 | SPACER DEVICE WITH FLOW RATE SPIROMETER | AEROVU TECH INC (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114302886-A | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3976103-A1 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | Imbria Pharmaceuticals, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976101-A1 | METHODS OF TREATING FIBROSIS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | Imbria Pharmaceuticals, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3968981-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3971179-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-03-23 | — | — | EP | disclosed |
| CN-114173774-A | Compounds for the treatment of neurodegenerative and metabolic disorders | 斯克里普斯研究院 | 2022-03-11 | — | — | CN | disclosed |
| EP-3950683-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590094-B2 | Compounds for the treatment of neurodegenerative and metabolic disorders | TXN2, SMN1; SMN2, SNCA | GABRG2 4545/4885GABRB3 3739/4885GABRA5 4123/4885 |
| US-20260060978-A1 | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS | TNNT2, TNNC1, CPT1B | GABRG2 1503/4885GABRB3 1662/4885GABRA5 1020/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | GABRG2 17/4885GABRB3 12/4885GABRA5 9/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | GABRG2 15/4885GABRB3 6/4885GABRA5 1/4885 |
| US-20260077139-A1 | SPACER DEVICE WITH FLOW RATE SPIROMETER | TMCO1, CFTR, CYSLTR2 | GABRG2 2309/4885GABRB3 2292/4885GABRA5 1119/4885 |
| US-12569480-B2 | Methods of treating fibrosis using compounds that promote glucose oxidation | CPT1B, PFKP, PTK2 | GABRG2 3801/4885GABRB3 3117/4885GABRA5 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.